

Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy

NCT06102694

Status RECRUITING
Sponsor Institute of Hematology & Blood Diseases Hospital, China
Enrollment 500 participants

Key Eligibility Criteria

Inclusion (4)

- Diagnosis of a hematologic disease (e.g., leukemia, myelodysplastic syndromes, lymphoma) confirmed by histology or other appropriate diagnostic methods.
- \. undergoing allo-HSCT
- \. Age 14 years or older
- Informed consent must be signed before the start of the study. For participants aged 18 and above, the informed consent should be signed by the patient or their immediate family member. Considering the patient's condition, if it is not favorable for the patient to sign, the informed consent may be signed by a legal guardian or immediate family member of the patient.

Exclusion (4)

- \. Missing or lost follow-up of key clinical data
- \. failure to collect plasma samples at specific time points after transplantation
- \. Plasma sample collection time later than the onset date of TMA
- \. TMA occurrence time later than 180 days after transplantation

Locations (1 total)

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China